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Abstract
Protoporphyria (PP) is caused by a deficiency of ferrochelatase (FC) activity, which catalyzes the final step in the heme
biosynthesis pathway. Bovine are the only species other than man with naturally occurring PP. For expression of the PP
phenotype, two copies of the mutated gene are necessary in bovine, whereas one copy is sufficient in humans. We report the
first potential disease-causing mutation in the bovine FC gene. The coding region of FC was sequenced from the liver tissue
of protoporphyric and normal bovine. A transversion was identified at nucleotide position 1250 which changed the stop
codon to leucine (TGACTTA) in the protoporphyric FC sequence. As a consequence, the mutant protein is predicted to
have an additional 27 amino acids. To screen other bovine for the GCT transversion, cDNAs from liver tissue of clinically
and biochemically normal, and from heterozygous and homozygous affected animals were used for allele-specific polymerase
chain reaction. Three normal animals had only the G allele, five affected animals had only the T allele, and three
heterozygous animals had both the G and T alleles. These results support our hypothesis that this mutation causes PP in
bovine. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Protoporphyria (PP) is a genetic disease in humans
characterized biochemically by an increase in eryth-
rocyte and fecal protoporphyrin levels and a decrease
in ferrochelatase (FC) activity [1,2]. FC is the termi-
nal enzyme in the heme biosynthesis pathway and
catalyzes the insertion of ferrous iron into protopor-
phyrin to form heme. A decrease in FC activity leads
to excessive accumulation of protoporphyrin, the im-
mediate precursor of heme. Because of its photoreac-
tive property, accumulation of protoporphyrin
causes photosensitivity, which is the major clinical
symptom of PP. In human patients, progressive liver
damage may also occur because of the toxic e¡ect of
protoporphyrin accumulation in liver cells [3,4].
The only known naturally occurring animal model
is in cattle [5]. FC de¢ciency has also been observed
in the house mouse after chemical mutagenesis ex-
periments with ethylnitrosourea (ENU) [6]. The ma-
jor di¡erence between the human and bovine diseases
is that bovine require two copies of the mutated gene
0925-4439 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 8 ) 0 0 0 5 2 - 0
* Corresponding author. Fax: (205) 9759393;
E-mail : j_bloomer@gasmac.dom.uab.edu
BBADIS 61756 8-10-98
Biochimica et Biophysica Acta 1408 (1998) 18^24
whereas humans need only one copy to express the
PP phenotype, since most cases of human PP are
inherited as autosomal dominant diseases. However,
a more complex mode of inheritance has been postu-
lated in humans in which there is coinheritance of the
mutant FC allele together with a low expressing ‘nor-
mal’ FC allele [7]. FC activity in ¢broblasts and liv-
ers of normal bovine is higher than in normal human
tissue [8,9]. Thus, the level of FC activity in tissues of
a heterozygous animal may be su⁄cient to prevent
accumulation of protoporphyrin.
FC (EC 4.99.1.1) has been puri¢ed from both hu-
man and bovine tissue. It is located on the inner
mitochondrial membrane [10,11], and studies with
radiation inactivation have shown that the functional
size of FC in bovine liver mitochondria is approx. 80
kDa [12]. This observation suggests that FC func-
tions as a homodimer in the mitochondria because
the molecular mass of puri¢ed FC has been reported
as 40^42 kDa in several mammalian species [13].
Both human [14] and bovine [15] FC have been
cloned and sequenced. The FC gene contains 11
exons and is approx. 45 kilobases in length. In hu-
mans, the gene maps to 18q21.3 [16]. The nucleotide
sequences of the two genes have 86% homology [15].
However, at the site of the human start codon
(ATG), a GGG is found in bovine. The bovine start
codon (ATG) is located seven codons downstream
from the human start codon. The N-terminal amino
acid of mature bovine FC is preceded by a 47-residue
mitochondrial-targeting leader peptide [15]. A num-
ber of mutations in the human FC gene have been
reported to cause PP [17]. However, no disease-caus-
ing mutation in bovine has been reported to date.
In this study, we identi¢ed a novel mutation in
exon 11 of the bovine FC gene that changes the
stop codon to leucine (X417L). The mutant protein
contains an additional 27 amino acids on its carboxyl
terminal end. We provide evidence that the mutation
is disease-causing and not a polymorphism.
2. Materials and methods
2.1. Population studied
Liver tissue was collected from ¢ve animals who
were diagnosed with protoporphyria based on photo-
sensitivity and elevated erythrocyte protoporphyrin
levels (range of 12 687^24 902 Wg/dl compared to nor-
mal range of 139^229 Wg/dl [8]). Three of these ani-
mals were con¢rmed to be homozygous by direct
measurement of FC activity in liver tissue (4, 6,
and 11% of the normal mean). Liver tissue was
also collected from three animals presumed to be
heterozygous because they were parents of a¡ected
animals who were not part of this study. None of
these animals had photosensitivity and protopor-
phyrin levels were normal or borderline elevated. Ad-
ditional evidence for heterozygosity was based on
measurements of FC activity in liver tissue (31, 35,
and 55% of the normal mean). Liver tissue from two
normal animals was collected and used in the study
as well as commercially derived normal bovine liver
mRNA (Clontech, Palo Alto, CA). To our knowl-
edge, none of the animals included in this study were
immediate relatives.
2.2. RNA isolation and cDNA synthesis
Total RNA was isolated from 20 mg liver tissue of
¢ve homozygous a¡ected, three heterozygous, and
two una¡ected animals. The pre-weighed frozen tis-
sue was transferred from 380‡C to liquid nitrogen.
Liver tissue was ground into a ¢ne powder and total
RNA was prepared using acid guanidinium thiocya-
nate-phenol-chloroform extraction [18]. The total
RNA was digested with 10 U DNase I, RNase-free
(Boehringer-Mannheim, Indianapolis, IN). Two
micrograms of each prepared RNA species as well
as commercially derived normal bovine liver
mRNA (Clontech, Palo Alto, CA) were used as tem-
plate for ¢rst strand cDNA synthesis. A 20 Wl reac-
tion volume containing 1UFirst Strand bu¡er
(50 mmol/l Tris-HCl (pH 8.3), 75 mmol/l KCl,
3 mmol/l MgCl2), 5 mmol/l dithiothreitol (DTT)
(Gibco BRL, Gaithersburg, MD), 0.75 mmol/l each
dNTP (Boehringer Mannheim), 2 Wg random hexa-
nucleotide primer (Pharmacia, Uppsala, Sweden),
and 200 U Superscript II reverse transcriptase (Gibco
BRL) was used. Random hexamers were polymerized
along RNA templates for 10 min at 25‡C followed
by 75 min at 42‡C with inactivation of the reverse
transcriptase for 5 min at 70‡C. Residual RNAs were
digested with 1.5 units RNase H (Promega, Madison,
WI) for 20 min at 37‡C.
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2.3. Polymerase chain reaction (PCR)
Total cDNAs were used as templates in PCR. The
3P end of the FC cDNA was ampli¢ed using primers
S1100, 5P-GTGAGTGTGGACTTGAAAACA-3P,
and AS1440, 5P-GCCCCTTCCTGGAGAAAG-3P.
Ampli¢cation was performed in a GeneAmp PCR
system 2400 (Perkin-Elmer Cetus, Norwalk, CT) us-
ing a 50 Wl reaction volume containing 1UPCR buf-
fer (20 mmol/l Tris-HCl (pH 8.4), 50 mmol/l KCl),
2 mmol/l MgCl2, 2 U Taq DNA polymerase,
0.2 mmol/l of each dNTP (Gibco BRL), and
10 pmol of each primer. PCR conditions were:
94‡C, 2 min, followed by 40 cycles of 94‡C, 20 s;
58‡C, 40 s; and 72‡C, 1 min; with an additional
extension at 72‡C, 6 minutes. PCR products were
resolved by agarose gel electrophoresis on 1% gels
and visualized by ethidium bromide staining. PCR-
ampli¢ed cDNA fragments were excised from gels
and puri¢ed using a QIAEX II gel extraction kit
(Qiagen, Hilden, Germany). Gel puri¢ed PCR prod-
ucts were direct sequenced on an ABI 377 sequencer
(UAB Automated DNA Sequence Facility, Depart-
ment of Microbiology).
2.4. Subcloning and nucleotide sequencing
The gel puri¢ed 294 bp PCR products of the 3P
end of FC from ¢ve protoporphyric and two normal
bovine were subcloned in pCR2.1 (Invitrogen, San
Diego, CA) and transformed into Escherichia coli
cells. Plasmid DNA from positive transformants
was puri¢ed using Wizard Plus SV Minipreps DNA
Puri¢cation System (Promega) and sequenced on an
ABI 377 sequencer (UAB Automated DNA Se-
quence Facility, Department of Microbiology).
2.5. Western blot analysis
Mitochondrial fractions from normal and proto-
porphyric bovine livers containing 100 Wg total pro-
tein (by the bicinchoninic acid procedure, Pierce
Chemical, Rockford, IL) were solubilized in SDS-
PAGE loading bu¡er containing 10% SDS and L-
mercaptoethanol. The samples were heated to 94‡C
for 4 min followed by 10^20% SDS-PAGE (Ready
Made Gel, Bio-Rad, Hercules, CA) to separate the
proteins. A Kaleidoscope pre-stained marker (Bio-
Rad) was run alongside the samples to determine
protein sizes. Electrophoretic transfer of the proteins
in the gel to a nylon membrane was performed using
a Bio-Rad Trans-Blot Cell at 100 V for 1 h under
cooled conditions. The nylon membrane was subse-
quently blocked with 5% non-fat dry milk in PBS
prior to addition of a 1/500 diluted FC-speci¢c anti-
body [12]. The antibody was detected by addition of
a 1/500 diluted goat anti-rabbit IgG conjugated with
alkaline phosphatase (Bio-Rad) followed by incuba-
tion with bromochloroindolyl phosphate (BCIP) and
p-nitroblue tetrazolium (NBT).
2.6. Allele-speci¢c PCR (ASPCR)
To screen for the presence of the transversion
found by sequencing, cDNAs from three normal,
three heterozygous, and ¢ve homozygous a¡ected
bovine were used as templates for ASPCR [19,20].
Phenotypes were determined by the animal’s photo-
sensitivity, protoporphyrin level and/or FC activity.
The ¢rst round of PCR used primers S1100 and
AS1440 as described above. The second round of
PCR used ¢rst round PCR product as template in
two reactions, each containing one allele-speci¢c pri-
mer, 1250G or 1250T, along with the common down-
stream primer, AS1440. 1250G and 1250T have the
same sequence except that the nucleotide on the 3P
Fig. 1. The nucleotide sequences and translation products of
the 3P region of normal and mutant FC. The published stop co-
don has been altered (TGACTTA) in mutant FC creating a
protein with 27 additional amino acid residues. Lower case let-
ters represent the nucleotide sequence of FC cDNA beginning
with nucleotide 1243. Upper case letters represent the corre-
sponding amino acid residues. In mutant FC, the altered bases
are underlined.
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end of the primer is either a G or a T, respectively
(5P-ACCAGCCAGCAGCTGTG or T-3P). The sec-
ond round of PCR was performed under the same
conditions as the ¢rst round with the exception that
only ¢ve cycles of ampli¢cation were performed, the
annealing time was 30 s and the elongation time was
40 s. PCR products were separated by agarose gel
electrophoresis on 1% gels and visualized by ethidi-
um bromide staining.
3. Results
Sequence analysis of normal and a¡ected animals
revealed a transversion at nucleotide position 1250 in
two protoporphyric bovine liver cDNAs that
changed the stop codon to leucine (TGACTTA).
This transversion allows translation to continue to
the next in-frame stop codon located 27 amino acids
downstream from the published stop codon. Normal
bovine liver FC cDNA sequences were identical to
previously published FC nucleotide sequences (Gen-
Bank accession No. L34172) [15]. Three other nu-
cleotide substitutions were identi¢ed downstream
from the published stop codon in both protoporphy-
ric animals: CCA at nucleotide 1252, GCA at nu-
cleotide 1257, and CCT at nucleotide 1258 (Fig. 1).
To screen other bovine for the GCT transversion
within the stop codon and to determine whether it
was a potential disease-causing mutation, FC cDNA
was prepared from liver tissue of bovine with pheno-
types determined by clinical symptoms, protopor-
phyrin levels, and/or FC activities. cDNAs from
these animals were used for ASPCR, which selec-
tively ampli¢es speci¢c alleles, and detects known,
single-base substitutions. Two reactions were per-
formed with each cDNA sample. Each reaction con-
tained only one of the upstream allele-speci¢c pri-
Fig. 3. Western blot analysis of mitochondrial fractions from
protoporphyric (PP) and normal (N) bovine livers. 100 Wg total
protein was loaded in both lanes and the approx. 40 kDa pro-
tein was detected using a FC-speci¢c antibody. The standard
(Std.) used was a Kaleidoscope pre-stained marker (Bio-Rad).
Fig. 2. ASPCR results. The ¢rst round and allele-speci¢c round PCR products are labeled. Each sample requires two lanes, one for
the G allele (TGA) and one for the T allele (TTA). The allele-speci¢c PCR product identi¢es each genotype. The lanes labeled M are
123 bp DNA ladders, lanes 1^3 are una¡ected animals, lanes 4^6 are heterozygous animals, lanes 7^11 are homozygous a¡ected ani-
mals and lane 12 is a negative control.
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mers, while the downstream primer was common to
both alleles. Thus, e⁄cient ampli¢cation occurs only
in the reaction with the complementary allele-speci¢c
primer and not in the reaction with the 3P mismatch.
Using this technique, only the G allele was detected
in the three normal bovine, only the T allele in the
¢ve homozygous a¡ected bovine, and both the G
and T alleles in the three heterozygous bovine (Fig.
2). Genomic FC DNA prepared from liver tissue of
the animals gave the same results.
To determine whether all a¡ected bovine had the
three nucleotide substitutions that were located
downstream from the published stop codon muta-
tion, the three protoporphyric bovine whose FC
cDNAs were not originally sequenced were ampli¢ed
using primers S1100 and AS1440, and the products
were sequenced. The three nucleotide substitutions
(1252CCA, 1257GCA, 1258CCT), in addition to
the transversion in the stop codon, were identi¢ed in
all ¢ve.
Analysis by Western blot hybridization showed
that the FC-speci¢c antibody complexed to a protein
of approx. 40 kDa in liver mitochondria from the
normal animal, as expected, whereas it appeared to
complex to a slightly larger protein in the protopor-
phyric animal. These bands were of equal intensity.
However, the size di¡erential between the proteins
could not be clearly distinguished (Fig. 3).
4. Discussion
Protoporphyria is well documented in bovine, but
no disease-causing mutation has previously been re-
ported. We searched for the disease-causing mutation
by sequencing liver-derived cDNA from protopor-
phyric bovine and comparing the sequence to that
of normal bovine. A transversion was identi¢ed in
the transcript of two protoporphyric bovine
(1250GCT) that changed the stop codon to leucine
(X417L).
To determine that 1250GCT was speci¢cally as-
sociated with bovine PP and to determine that it was
a potential disease-causing mutation rather than a
polymorphism, ASPCR was used to screen bovine
with clinically determined phenotypes. The GCT
transversion that changes the stop codon to leucine
was found in all ¢ve cattle clinically determined to be
protoporphyric. Normal bovine were devoid of this
transversion and those determined to be heterozy-
gous had one copy of the normal and one copy of
the mutant allele, suggesting that this is the disease-
causing mutation in these animals.
All ¢ve protoporphyric bovine were additionally
found to have three nucleotide substitutions down-
stream from the stop codon (1252CCA, 1257GCA,
1258CCT). This region within the FC gene may be
a ‘hot spot’ for nucleotide substitutions. On the other
hand, the three nucleotide substitutions may have
been generated by a founder e¡ect since they were
found in all ¢ve a¡ected bovine studied. The founder
e¡ect supports the hypothesis that most, if not all,
a¡ected bovine are descendants of one sire in the
USA [5]. To determine whether the occurrence of
these three nucleotide substitutions located down-
stream from the X417L mutation in the ¢ve a¡ected
bovine signify the propagation of an ancestral allele
or are part of a mutational ‘hot spot’, it is necessary
to determine haplotypes using informative polymor-
phisms within the FC gene.
The three additional nucleotide substitutions by
themselves do not cause protoporphyria since they
are not within the coding region. However, both
1252CCA and 1258CCT alter the amino acid com-
position of the mutant protein compared to that
which is predicted if the X417L mutation is alone.
Thus, there is a possibility that one or both are in-
£uencing the decrease in FC activity. There are ex-
amples reported of polymorphisms combining with
pathogenic mutations to create di¡erent disease phe-
notypes. Two altered conformations of the prion
protein are produced depending on the polymor-
phism at codon 129. In combination with a single
pathogenic mutation at codon 178, a methionine at
codon 129 causes a phenotype of fatal familial in-
somnia while a valine at codon 129 gives a pheno-
type of 178Asn CJD, a subtype of familial Creutz-
feldt-Jakob disease [21].
Previous studies in our lab indicated that the FC
defect in bovine reduced catalytic activity of the en-
zyme but did not alter its cross-reaction with anti-
body prepared against normal FC protein (a CRIM-
positive mutation) [22]. Western blot results from
this study support the contention that this is a
CRIM-positive mutation. The additional 27 amino
acids that are predicted to be present on the carboxyl
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terminal end of the mutant FC protein are glutamate
and proline rich. This may cause interference on
SDS-PAGE and thus explain why it was di⁄cult to
determine a size di¡erence between the normal and
mutant proteins. A [2Fe-2S] cluster has been identi-
¢ed on the carboxyl terminal end of FC that has an
important role in its catalytic function. Dailey et al.
[23] have reported that mutations in this area cause a
signi¢cant reduction in enzyme activity. Thus, the
additional 27 amino acids may interfere with cata-
lytic function by disrupting the [2Fe-2S] cluster.
Studies to address this possibility will be undertaken.
The bovine FC nucleotide coding region is 86%
homologous to the human FC coding region [15].
To date there have been no reported mutations lo-
cated in the stop codon of the human FC gene. How-
ever, knowledge of the disease-causing mutation in
protoporphyric bovine will be useful for cattle
breeders. The ASPCR assay can be used to screen
bovine for this particular mutation. In particular,
heterozygous animals can be clearly distinguished
from normal animals.
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